68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review
- 806 Downloads
To systematically review currently available data on 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) used for the primary staging of high-risk prostate cancer.
We performed critical reviews of EMBASE, Web of Science (including MEDLINE) and Cochrane databases in October 2016 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. We included studies that utilized 68Ga-PSMA PET for primary staging of prostate cancer. Quality was assessed using the Critical Appraisal Skills Programme checklist for diagnostic test studies.
Following our systematic search strategy, 12 studies were included for assessment. These studies comprised a total of 322 patients who underwent 68Ga-PSMA PET scanning for the purpose of primary staging. Only 5 of these studies included histopathologic correlation data. High variation in methodology and outcomes such as sensitivity (range 33–99%) and specificity (> 90%) was seen across all studies. The ability of 68Ga-PSMA PET to detect malignant lesions was evident across studies, with most studies demonstrating increased detection rates with respect to conventional imaging modalities.
In the primary staging of prostate cancer 68Ga-PSMA PET appears to outperform traditional imaging modalities. Overall, there are few high-quality studies investigating 68Ga-PSMA PET in this sub-group highlighting the need for formal assessment of PSMA PET in the form of large-volume, prospective studies.
KeywordsProstate cancer Imaging Positron emission tomography Prostate-specific membrane antigen PSMA
We would like to acknowledge the support of the Young urology researchers organisation (YURO) community of Australia and New Zealand for enabling this manuscript to progress to completion.
All authors in the submitted article have made a substantial contribution to the information submitted for publication. JC: protocol/project development, data collection or management, data analysis, manuscript writing/editing. MP: protocol/project development, data collection or management, data analysis, manuscript writing/editing. DB: protocol/project development. NL: protocol/project development, Manuscript writing/editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study formal consent is not required.
- 3.Mottet NBJ, Briers E, Bolla M, Cornford P, De Santis M, Henry A, Joniau A, Lam T, Mason MD, Matveev V, van der Kwast TH, van der Poel H, Rouvière O, Wiegel T; members of the EAU–ESTRO–SIOG prostate cancer guidelines Panel., EAU–ESTRO–SIOG guidelines on prostate cancer. Edn. Presented at the EAU Annual Congress MI—PEGO. https://uroweb.org/guideline/prostate-cancer/. Accessed 26 Mar 2017
- 12.Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA et al (2013) PET imaging with a [68 Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40(4):486–495CrossRefPubMedGoogle Scholar
- 13.Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG et al (2016) Sensitivity, specificity, and predictors of positive 68 Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70(6):926–937CrossRefPubMedGoogle Scholar
- 14.Critical Appraisal Skills Programme. CASP (Diagnostic Test Study) Checklist 2017 [cited 2017 October 28]. http://www.casp-uk.net/casp-tools-checklists
- 17.Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C et al (2016) 68 Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 70(4):553–557CrossRefPubMedGoogle Scholar
- 20.Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G et al (2016) Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195(5):1436–1443CrossRefPubMedGoogle Scholar
- 25.Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D et al (2017) 68 Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 44:941–946CrossRefPubMedGoogle Scholar
- 26.van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q et al (2017) Prospective evaluation of 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 119(2):209–215CrossRefPubMedGoogle Scholar